Skip to main content
. Author manuscript; available in PMC: 2013 Aug 1.
Published in final edited form as: Int J Radiat Oncol Biol Phys. 2012 Aug 1;83(5):e655–e660. doi: 10.1016/j.ijrobp.2012.01.061

Table 2.

Clinical characteristics of patients with necrosis

Age
(yr)/Sex		 Risk
Group		 Time to
Necrosis
Imaging		 Time to
Necrosis
Symptomatic		 Neurological
Deficits		 Grade Treatments
and
Interventions		 Time to
Imaging
Resolution
6.9/F AR 9.8 NA None 1 None 84.6
10.9/M AR 2.5 6.1 CN Deficits 3 Dexamethasone HBOT, Gtube 7.1
10.7/F AR 2.8 5.5 CN deficits 3 Dexamethasone HBOT, LMWH 53.2
5.4/M HR 5.5 6.9 CN Deficits 3 Dexamethasone 6.3
9.0/F HR 2.7 4.2 Respiratory Failure 4 Dexamethasone tracheostomy, Gtube NA
6.7/F HR 4.8 5.7 CN Deficits, Quadriplegia, Respiratory Failure 4 Dexamethasone HBOT, Bevacizumab, tracheostomy NA
3.9/M AR 4.9 7.9 Quadriplegia, Respiratory Failure 4 Dexamethasone Tracheostomy, Gtube 12.7
8.3/M HR 5.0 6.0 Quadriplegia, Respiratory Failure 5 Dexamethasone Tracheostomy, Gtube NA

Abbreviations: CN = cranial nerve HBOT = hyperbaric oxygen therapy; LMWH = low molecular weight heparin; AR = average-risk; HR = high-risk.